Back
Nuveen S&P 500 Buy-Write Income Fund Vs. Halozyme Therapeutics Industry Stock Comparison
Sell
48
BXMX
Nuveen S&P 500 Buy-Write Income Fund
Last Price:
13.78
Seasonality Move:
0.38%
Sell
39
HALO
Halozyme Therapeutics
Last Price:
45.65
Seasonality Move:
17.03%
Sell
48
Nuveen S&P 500 Buy-Write Income Fund (BXMX)
is a Sell
Is Nuveen S&P 500 Buy-Write Income Fund a Buy, Sell or Hold?
- The current Nuveen S&P 500 Buy-Write Income Fund [BXMX] share price is $13.79. The Score for BXMX is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
- BXMX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
39
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics a Buy, Sell or Hold?
- The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
- HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
BXMX Stock Price Chart
What is Nuveen S&P 500 Buy-Write Income Fund's stock price today?
-
The Nuveen S&P 500 Buy-Write Income Fund share price today is $13.79
The current trend is moderately bullish and BXMX is experiencing slight buying pressure.
HALO Stock Price Chart
What is Halozyme Therapeutics's stock price today?
-
The Halozyme Therapeutics share price today is $45.65
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.
BXMX Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.05 | Buy |
| Relative Strength Index (14 RSI): | 52.38 | Buy |
| Chaikin Money Flow: | 13438 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (13.68 - 13.86) | Buy |
| Bollinger Bands (100): | (13.23 - 13.77) | Buy |
HALO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.02 | Sell |
| Relative Strength Index (14 RSI): | 30.2 | Sell |
| Chaikin Money Flow: | -7140517 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (49.94 - 58.56) | Sell |
| Bollinger Bands (100): | (52.16 - 60.38) | Sell |
BXMX Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 13.86 | Sell |
| 20-day SMA: | 13.77 | Buy |
| 50-day SMA: | 13.67 | Buy |
| 200-day SMA: | 13.3 | Buy |
| 8-day EMA: | 13.82 | Sell |
| 20-day EMA: | 13.78 | Buy |
| 50-day EMA: | 13.67 | Buy |
| 200-day EMA: | 13.35 | Buy |
HALO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 57.53 | Sell |
| 20-day SMA: | 54.48 | Sell |
| 50-day SMA: | 56.18 | Sell |
| 200-day SMA: | 48.93 | Sell |
| 8-day EMA: | 55 | Sell |
| 20-day EMA: | 55.41 | Sell |
| 50-day EMA: | 55.64 | Sell |
| 200-day EMA: | 50.73 | Sell |
Nuveen S&P 500 Buy-Write Income Fund Earnings Growth & BXMX Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Halozyme Therapeutics Earnings Growth & HALO Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.
Nuveen S&P 500 Buy-Write Income Fund Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Halozyme Therapeutics Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||